Thu, 14 Sep 2017 12:00:00 EDT Priming Exercise in Type 1 Diabetes Condition: Type 1 Diabetes Mellitus Intervention: Behavioral: Priming exercise Sponsor: Liverpool Hope University Not yet recruiting - verified September 2017
Thu, 14 Sep 2017 12:00:00 EDT Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Conditions: Chronic Pancreatitis; Insulin Dependent Diabetes Interventions: Drug: Hydroxychloroquine; Drug: Placebo Sponsors: The Cleveland Clinic; Allegheny Singer Research Institute; Stanford University Not yet recruiting - verified September 2017
Wed, 13 Sep 2017 12:00:00 EDT ZIMBA: Clinical Trial in Paediatric Obesity Conditions: Obesity, Childhood; Insulin Resistance; Zinc Deficiency; Inositol Interventions: Dietary Supplement: Zinc and Myo-inositol; Drug: Placebos Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita Not yet recruiting - verified September 2017
Wed, 13 Sep 2017 12:00:00 EDT Beta Adrenergic Antagonist for the Healing of Chronic DFU Conditions: Chronic Diabetic Foot Ulcers; Diabetic Neuropathic Ulcers; Non Healing Wound Interventions: Drug: Timolol; Drug: Non biologically active gel Sponsors: VA Office of Research and Development; VA Northern California Health Care System Not yet recruiting - verified September 2017
Tue, 12 Sep 2017 12:00:00 EDT Incretin and CRTd. Conditions: Type 2 Diabetes Mellitus; Heart Failure Interventions: Drug: Incretin Effect; Device: Cardiac Resynchronization therapy defibrillator device Sponsor: University of Campania "Luigi Vanvitelli" Completed - verified September 2017
Tue, 12 Sep 2017 12:00:00 EDT Protein Intake and Step Reduction in Older Adults Conditions: Aging; Muscle Loss Interventions: Dietary Supplement: Whey; Dietary Supplement: Collagen Sponsors: McMaster University; National Dairy Council Active, not recruiting - verified September 2017
Tue, 12 Sep 2017 12:00:00 EDT
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Thu, 14 Sep 2017 13:48:00 -0400 FDA approves new treatment for adults with relapsed follicular lymphoma The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.
Thu, 14 Sep 2017 12:56:00 -0400 FDA approves first biosimilar for the treatment of cancer The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Thu, 14 Sep 2017 12:11:00 -0400 FDA permits marketing of mobile medical application for substance use disorder Today, the U.S. Food and Drug Administration permitted marketing of the first mobile medical application to help treat substance use disorders (SUD). The Reset application is intended to be used with outpatient therapy to treat alcohol, cocaine, marijuana and stimulant SUDs. The application is not intended to be used to treat opioid dependence.
Thu, 07 Sep 2017 12:32:00 -0400 FDA clears mammography device with option for patient-assisted compression Today, the U.S. Food and Drug Administration cleared the first 2D digital mammography system that allows patients to increase or decrease the amount of compression applied to their own breast before the mammogram x-ray is taken.
Fri, 01 Sep 2017 15:07:00 -0400 FDA approves Mylotarg for treatment of acute myeloid leukemia The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
Thu, 31 Aug 2017 11:08:00 -0400 FDA approval brings first gene therapy to the United States The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.
Wed, 30 Aug 2017 10:41:00 -0400 FDA approves new antibacterial drug The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.
